The FDA has approved Duavee (Pfizer), a fixed-dose combination of conjugated estrogens and the new selective estrogen receptor modulator (SERM) bazedoxifene, for treatment of moderate to severe vasomotor symptoms and for prevention of osteoporosis in postmenopausal women with an intact uterus. Bazedoxifene is an estrogen agonist/antagonist with estrogen-like effects on bone and antiestrogen effects on the uterus. It is the second SERM to be approved for prevention of osteoporosis; raloxifene (Evista, and generics) has been available as a single agent for this indication since 1997.

HORMONAL THERAPY — Systemic estrogen is the most effective treatment for menopausal vasomotor symptoms; it decreases hot flushes by 50-100% within 4 weeks.1 However, women with an intact uterus who take systemic estrogen are advised to also take an oral progestin to reduce the risk ... more      

Would you like to read the rest of this article?  Gain access below.